Comparative Pharmacology
Head-to-head clinical analysis: AYGESTIN versus PROMETRIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AYGESTIN versus PROMETRIUM.
AYGESTIN vs PROMETRIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial changes by binding to progesterone receptors.
Progesterone binds to progesterone receptors in target tissues, promoting endometrial maturation, reducing uterine contractility, and suppressing ovulation.
5 mg orally once daily for secondary amenorrhea; 5 mg orally once daily from day 5 to day 25 of menstrual cycle for abnormal uterine bleeding.
Oral: 200 mg once daily at bedtime for 12 consecutive days per 28-day cycle in combination with conjugated estrogens 0.625 mg daily. For secondary amenorrhea: 400 mg once daily at bedtime for 10 days. Intravaginal: 4% gel (90 mg) or 8% gel (180 mg) applied every other day for 6 doses in postmenopausal women with intact uterus on estrogen therapy.
None Documented
None Documented
Terminal half-life 5-12 hours; clinical context: requires twice-daily dosing for consistent serum levels.
Terminal half-life: Approximately 16-18 hours for oral micronized progesterone (Prometrium); permits twice-daily dosing for luteal phase support.
Approximately 50-80% renal as metabolites, 10-20% fecal; less than 1% unchanged.
Urine (50-60% as metabolites, <1% unchanged); feces (20-30% as metabolites); minor biliary elimination.
Category C
Category C
Progestin
Progestin